News
Last week, Citron's Andrew Left announced a short position against Palantir, suggesting that the stock was "beyond overvalued ...
Regeneron Pharmaceuticals (NASDAQ:REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results